• AnBogen Therapeutics

  Led · Series A · Jul 2024

  Anbogen Therapeutics is a clinical-stage biotechnology company based in Taipei, Taiwan, focused on developing precision anti-cancer therapies. The company was founded by Dr. Joe Shih and is committed to R&D innovations to improve cancer patient outcomes. Two of its investigational drugs, ABT-101 for NSCLC with HER2 exon20 insertion mutations and ABT-301 (to be combined with immune checkpoint inhibitors) are currently in human clinical trials. Anbogen raised funding in a Series A+ to advance its pipeline. The company intends to use the proceeds to support a Phase II clinical trial of ABT-301 in combination with PD-1 inhibitors for microsatellite stable (MSS) metastatic colorectal cancer. The company highlights MSS metastatic colorectal cancer as comprising about 95% of the metastatic colorectal cancer population that does not benefit from immune checkpoint inhibitors. Anbogen Therapeutics is a clinical-stage biotech headquartered in Taipei, Taiwan, focused on developing precision anti-cancer small molecules. The company’s two lead candidates are ABT-101, a HER2-targeting tyrosine kinase inhibitor, and ABT-301, a small molecule that potentiates immune checkpoint inhibitors. ABT-101 has shown substantial potency and safety in preclinical studies and a phase 1b trial, with superior selectivity against HER2 exon 20 insertion mutations. ABT-301 completed a phase 1 trial and demonstrated superior safety and pharmacokinetic profiles versus similar marketed drugs; repeated animal studies show strong synergy with anti-PD‑1/PD‑L1 therapies, including activity in MSS colorectal cancer models and modulation of the tumor microenvironment to increase killer T cell infiltration. The company says clinical signs of safety and benefit have been observed in non-small cell lung cancer patients, including sustained tumor suppression in patients previously resistant to Enhertu. Led by CEO Dr. Tsu-An Hsu and General Manager Joe Hsueh, Anbogen positions its programs to address national medical needs and accelerate development toward improved cancer treatments.

• ASLAN Pharmaceuticals

  Participated · Equity · Jul 2016

  ASLAN Pharmaceuticals is a biopharmaceutical company developing ASLAN003 for autoimmune gastrointestinal and skin diseases and certain skin conditions. The company has closed a secured loan facility with K2 HealthVentures providing up to $45 million of secured debt financing. The facility includes a $20 million initial term loan funded at closing and a further $25 million subject to certain terms and conditions. ASLAN intends to use the proceeds to advance the clinical development of ASLAN003 and for general corporate purposes. The company expects to initiate a Phase 2 clinical trial of ASLAN003 in inflammatory bowel disease in early 2022. The loan provides near-term funding to support those planned clinical activities. ASLAN Pharmaceuticals is a biotech focused on developing immunotherapies and targeted agents for tumour types highly prevalent in Asia. Its pipeline comprises four novel therapeutic agents, with lead drug varlitinib currently in phase 2 trials for cholangiocarcinoma, gastric cancer and breast cancer. Proceeds from the new financing will be used to support clinical development of the pipeline. The company said the financing bolsters its financial position and will accelerate progress across its clinical programme. ASLAN has raised over US$100 million to date, including a US$43 million Series C in December 2015 led by Accuron (a Temasek subsidiary). The announcement was released from Singapore and the company is pursuing growth in Taiwan and the region. Aslan Pharmaceuticals is a Singapore-based biotech focused on developing immunotherapies and targeted agents for tumor types prevalent in Asia. The company maintains a proprietary pipeline of four development-stage candidates addressing multiple indications including gastric and breast cancers and inflammatory diseases. Its most advanced programs are in phase 2: ASLAN001, a pan-HER inhibitor with phase 2 data in gastric cancer and trials in cholangiocarcinoma, breast cancer and gastric cancer; and ASLAN002, which targets RON, an immune checkpoint target, and cMET. Aslan also operates a global medical device and diagnostics division, Accuron MedTech, led by Abel Ang. The company is led by CEO Dr. Carl Firth and plans to use recent proceeds to accelerate clinical development of ASLAN001, which received Orphan Drug Designation in cholangiocarcinoma from the US FDA.

No current team members are available.